Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin-2

Anticancer Research

Volumn 21, Issue 1 B, 2001, Pages 669-677

  Yamaguchi, Y ^a   Ohta, K ^a   Shimizu, K ^a   Minami, K ^a   Noma, K ^a   Hihara, J ^a   Toge, T ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Adoptive immunotherapy; Cytotoxic T lymphocytes; Gastric cancer; Gene transfer; IL 2; Mixed lymphocyte tumor culture (MLTC)

Indexed keywords

CD3 ANTIGEN; HLA A2 ANTIGEN; INTERLEUKIN 2; NEOMYCIN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FLOW CYTOMETRY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; STOMACH CANCER;

ADENOCARCINOMA; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION; CELLS, CULTURED; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MUROMONAB-CD3; RECOMBINANT FUSION PROTEINS; STOMACH NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0035060606     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Structure and expression of a cloned cDNA for human interleukin-2
2. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
3. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials
4. Tumor- induced immune dysfunction
5. Therapy of renal cell carcinoma with interleukin-2 and lymphokine- activated killer cells: Phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen
6. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
7. Tumor-host interaction: Analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas
8. A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma
9. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma
10. Induction of autologous tumor- specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization
11. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition
12. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma
13. Cells and cytokines in immunotherapy and gene therapy of cancer
14. Immunotherapy of cancer using cytokine gene-modified tumor vaccines
15. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary, generation of murine antiturnor cytolytic T lymphocytes in vitro
16. T cell response to embryonal carcinoma F9 cells: Induction and characterization of T cell receptor alpha beta+ double-negative cytotoxic T lymphocytes
17. Replication-defective chimeric helper proviruses and factors affecting generation of competent virus: Expression of Moloney murine leukemia virus structural genes via the metallothionein promoter
18. Retroviral expression of the human IL-2 gene in a murine T cell line results in cell growth autonomy and tumorigenicity
19. A human T cell line established from a patient with Sezary syndrome
20. Immunological properties of tumor cells genetically modified to secrete interleukin-2
21. Retrovirus-mediated gene transduction into long-term repopulating marrow cells of dogs
22. Toward a predictive understanding of molecular recognition
23. Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent
24. T cell clonal anergy
25. Bladder cancer immunogenicity: Expression of CD80 and CD86 is insufficient to allow primary, CD4+ T cell activation in vivo
26. Strong immunogenic potential of a B7 retroviral expression vector: Generation of HLA-B7-restricted CTL response against selectable marker genes
27. A feasible method for expression of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients
28. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathway
29. CD4+ T cells kill HLA-classII-antigen- positive melanoma cells presenting peptide in vitro
30. The rote of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity
31. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
32. Interleukin-2 production by tumor cells by-pass T helper function in generation of an antitumor response